Rituximab Therapy in Pulmonary Alveolar Proteinosis: A Case Report

利妥昔单抗治疗肺泡蛋白沉积症:病例报告

阅读:1

Abstract

Autoimmune pulmonary alveolar proteinosis (PAP) is a rare lung condition characterized by the accumulation of surfactant proteins within the alveoli, leading to respiratory distress. We describe a 49-year-old female homemaker with a history of passive smoking and exposure to wood smoke and pigeon droppings. She presented with a dry cough and progressive dyspnea, experiencing significant deterioration in her condition over one year. Chest imaging revealed bilateral alveolar-interstitial syndrome with ground-glass opacities and alveolar condensations. Biopsy findings indicated type II pneumocytes and eosinophilic material, confirming a diagnosis of autoimmune PAP. After ruling out secondary causes of PAP, rituximab was administered successfully, leading to marked improvement in respiratory function and significant regression of radiological lesions within two months. This case highlights the importance of early diagnosis and treatment of autoimmune PAP, demonstrating the potential efficacy of rituximab in managing this challenging condition.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。